EP300 and melanoma: MITFlow melanoma status may therefore serve as a biomarker for tumors which would be most sensitive to inhibition of invasion and metastasis through p300 KAT inhibition, perhaps as a preventative therapeutic agent for patients with MITFlow primary melanomas.